Résultats de recherchePour la revue "Addiction" :  41 articles trouvés.

Addictions aux opiacés  Article original (Abstract) | Publié le 17-11-2023
  Thomas Soeiro et al. | Addiction 2023; 118(10): 1984-93
Non‐medical use of prescription drugs is an unmitigated public health issue that has been developing for decades in many countries world‐wide [1]. While opioids gain most awareness due to the ongoing opioid epidemic, non‐medical use of prescription drugs and subsequent harm are not restricted to this pharmacological class. Concern involves many drugs, such as benzodiazepines and non‐benzodiazepine...

Addictions aux opiacés  Article original (Abstract) | Publié le 15-09-2023
  Marion Robert et al. | Addiction 2023; 118(4): 771-5
The opioid epidemic has become a major concern with public health, social and economic consequences in some countries. Over the past 20 years, an increasing use of opioids has been reported in the United States, coinciding with an increase in opioid addiction * Additional information, including definitions of the most relevant concepts and outcome measures is provided in the Supporting information...

Addictions aux opiacés  Article original (Abstract) | Publié le 18-08-2023
  Tanya S. Hauck et al. | Addiction 2023; 118(10): 1953-64
During the past several decades and particularly the last several years, opioid use disorder (OUD) has resulted in exponentially increasing morbidity and mortality [1–8]. Buprenorphine–naloxone (hereafter ‘buprenorphine’) is an evidence‐based, first‐line treatment for OUD [9–12]. While methadone is another important treatment [13], buprenorphine use has increased...

Addictions aux opiacés  Article original (Abstract) | Publié le 17-05-2023
  Joanne Neale et al. | Addiction 2023; 118(7): 1329-39
New treatments for opioid use disorder have recently been developed, including long‐acting buprenorphine implants and injections [1–5]. This paper focuses on long‐acting injectable buprenorphine (LAIB). The first LAIB product (Sublocade) was approved for monthly use by the United States Food and Drug Administration in 2017 [6] and two additional products (weekly Buvidal and monthly...

Addictions aux opiacés  Article original (Abstract) | Publié le 03-05-2023
  Sarah Larney et al. | Addiction 2023; 118(8): 1527-39
Opioid agonist treatment (OAT) is associated with multiple beneficial outcomes for people with opioid dependence or opioid use disorder, notably reduced mortality across a range of causes [1]. The strongest reductions in mortality are observed in relation to fatal overdose, with risk of death due to unintentional opioid overdose reduced by 69% during OAT relative to periods out of treatment [1]. This...

Le point de l'expert  Article original (Abstract) | Publié le 20-03-2023 | Commenté par : Dr Karima Koubaa
  Carlos A. Monteiro et al. | Addiction 2023; 118(4): 603-4  |  The foods that are addictive
Le centre d’études épidémiologiques en santé et Nutrition de l’école de santé publique de Sao Paulo (Brésil) s’est intéressé à l’alimentation et à la possibilité de potentiel addictif.dans cet article.

Les critères d’addiction aux substances notamment le tabagisme peuvent...


798 articles actuellement disponibles

Rechercher

Besoin d'aide ?
Recherche avancée
Recherche par revues
Sélectionnez l'initiale de la revue recherchée
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0-9
Recherche par rubriques